摘要
目的:研究化合物Ⅰb作为一种AT1受体拮抗剂的拮抗活性。方法:分别以清醒自发性高血压大鼠、麻醉自发性高血压大鼠和肾性高血压大鼠为模型,测定化合物Ⅰb的降压活性。结果:在3种大鼠模型中,Ⅰb均可明显降低血压,最大降压幅度分别为17.1%,18.0%和18.0%,降压作用持续时间大约150 min。并且化合物Ⅰb在降压的同时对大鼠的心率无明显影响。结论:化合物Ⅰb作为一种新的抗高血压化合物具有广泛的研发前景。
AIM: To study the antagonistic effects of compound Ⅰb as a new angiotensin type 1 receptor antagonist. METHODS: Conscious spontaneously hypertensive rats (SHRs), anesthetized spontaneously and renal hypertensive rats (RHRs) were used to evaluate the antagonistic effects of compound Ⅰb. RESULTS: It was shown that the blood pressure in conscious SHR, anesthetized SHR and RHR was significantly reduced after intravenous administration of compound Ⅰb. The maximal extents of attenuation were 17.1%, 18.0% and 18.0%, respectively. The effect lasted about 150 minutes without heart rate being increased. CONCLUSION: These results suggest that compound Ⅰb is a potent, active AT1 receptor antagonist and potent in the treatment of hypertension.
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2005年第6期563-566,共4页
Journal of China Pharmaceutical University
基金
国家自然科学基金资助项目(No.30371688)
教育部重点基金资助项目(No.03089)~~
关键词
AT1受体拮抗剂
Ⅰb
自发性高血压
肾性高血压
抗高血压
Angiotensin receptor antagonists
Ⅰb
Spontaneously hypertension
Renal hypertension
Antihypertensive